Literature DB >> 36099142

Second-look Surgery for Appendiceal High Grade and Colorectal Cancers Following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Mohammad Breakeit1, Daniel Liu2, Adrian Cheng2, Hyerim Suh2, Shoma Barat2, Amer Matar2, Nayef Alzahrani2,3, David L Morris2,4.   

Abstract

BACKGROUND/AIM: Up to a third of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) of appendiceal or colorectal origin receive a stoma during primary surgery. Stoma reversal provides an opportunity for second-look surgery. PATIENTS AND METHODS: We performed a retrospective analysis of prospectively collected data of patients with colorectal cancer (CRC) or high-grade appendiceal cancer (AC) from 2006 to 2021 from our database. A total of 34 consecutive stoma closure patients with no evidence of preoperative disease recurrence (tumor markers and CT scans) were compared with 141 consecutive re-do CRS/HIPEC patients with known recurrence.
RESULTS: Eleven patients (32.4%) were identified to have peritoneal recurrence at stoma closure. Time between first and second CRS was 12 months (4 to 64.2) in the stoma closure group vs. 24.6 months (5.8 to 119.8) in the re-do group, while median peritoneal cancer index (PCI) was 4 (3 to 6) vs. 8 (1 to 39), respectively (p=0.0143).
CONCLUSION: Second-look laparotomy during stoma closure identified unexpected PC in 32.4% of our patients with significantly lower PCI than planned re-do operations.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Second-look; appendiceal; colorectal; completeness of cytoreduction; cytoreductive surgery; heated intraperitoneal chemotherapy; peritoneal cancer index; peritoneal carcinomatosis; peritonectomy; stoma-reversal

Mesh:

Year:  2022        PMID: 36099142      PMCID: PMC9463940          DOI: 10.21873/invivo.12966

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  32 in total

1.  Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.

Authors:  Diane Goéré; Olivier Glehen; François Quenet; Jean-Marc Guilloit; Jean-Marc Bereder; Gérard Lorimier; Emilie Thibaudeau; Laurent Ghouti; Amandine Pinto; Jean-Jacques Tuech; Reza Kianmanesh; Michel Carretier; Frédéric Marchal; Catherine Arvieux; Cécile Brigand; Pierre Meeus; Patrick Rat; Sylvaine Durand-Fontanier; Pascale Mariani; Zaher Lakkis; Valeria Loi; Nicolas Pirro; Charles Sabbagh; Matthieu Texier; Dominique Elias
Journal:  Lancet Oncol       Date:  2020-07-24       Impact factor: 41.316

2.  Surgical management for peritoneal carcinomatosis of appendiceal origin with a high-tumor burden.

Authors:  Toshiyuki Kitai; Kenya Yamanaka; Naoko Sugimoto; Osamu Inamoto
Journal:  Surg Today       Date:  2019-07-30       Impact factor: 2.549

3.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.

Authors:  P H Cashin; W Graf; P Nygren; H Mahteme
Journal:  Eur J Surg Oncol       Date:  2012-04-03       Impact factor: 4.424

4.  Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study.

Authors:  A S Cloutier; M Faron; C Honoré; D Goéré; F Dumont; F Vittadello; D Élias
Journal:  Eur J Surg Oncol       Date:  2015-04-03       Impact factor: 4.424

5.  PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries.

Authors:  Konstantinos Ioannis Votanopoulos; David Bartlett; Brendan Moran; Choudry M Haroon; Greg Russell; James F Pingpank; Lekshmi Ramalingam; Chandrakumaran Kandiah; Konstantinos Chouliaras; Perry Shen; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2017-12-29       Impact factor: 5.344

6.  Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.

Authors:  Cristian D Valenzuela; Edward A Levine; Christopher W Mangieri; Rohin Gawdi; Omeed Moaven; Gregory Russell; Megan E Lundy; Kathleen C Perry; Konstantinos I Votanopoulos; Perry Shen
Journal:  Ann Surg Oncol       Date:  2022-03-14       Impact factor: 4.339

7.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

Review 8.  Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement.

Authors:  Eelco de Bree; Wim Koops; Robert Kröger; Serge van Ruth; Arjen J Witkamp; Frans A N Zoetmulder
Journal:  J Surg Oncol       Date:  2004-05-01       Impact factor: 3.454

9.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

Authors:  Dominique Elias; François Gilly; Florent Boutitie; François Quenet; Jean-Marc Bereder; Baudouin Mansvelt; Gérard Lorimier; Pierre Dubè; Olivier Glehen
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Heather L Van Sweringen; Dennis J Hanseman; Syed A Ahmad; Michael J Edwards; Jeffrey J Sussman
Journal:  Surgery       Date:  2012-09-01       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.